The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
May. 20, 2008
Filed:
Mar. 08, 2002
Stephen F. Traynelis, Decatur, GA (US);
Dennis C. Liotta, Atlanta, GA (US);
James P. Snyder, Atlanta, GA (US);
Yesim Altas, Decatur, GA (US);
David D. Mott, Tucker, GA (US);
James J. Doherty, Jr., Landenberg, PA (US);
Raymond J. Dingledine, Atlanta, GA (US);
Stephen F. Traynelis, Decatur, GA (US);
Dennis C. Liotta, Atlanta, GA (US);
James P. Snyder, Atlanta, GA (US);
Yesim Altas, Decatur, GA (US);
David D. Mott, Tucker, GA (US);
James J. Doherty, Jr., Landenberg, PA (US);
Raymond J. Dingledine, Atlanta, GA (US);
Emory University, Atlanta, GA (US);
Abstract
NMDA receptor blockers, including pH-sensitive NMDA receptor blockers, are provided as neuroprotective drugs that are useful in stroke, traumatic brain injury, epilepsy, and other neurologic events that involve acidification of brain or spinal cord tissue. Compositions and methods of this invention are used for treating neurodegeneration resulting from NMDA receptor activation. The compounds described herein have enhanced activity in brain tissue having lower-than normal pH due to pathological conditions such as hypoxia resulting from stroke, traumatic brain injury, global ischemia that may occur during cardiac surgery, hypoxia that may occur following cessation of breathing, pre-eclampsia, spinal cord trauma, epilepsy, chronic pain, vascular dementia and glioma tumors. Compounds described herein are also useful in preventing neurodegeneration in patients with Parkinson's Alzheimer's, Huntington's chorea, ALS, and other neurodegenerative conditions known to the art to be responsive to treatment using NMDA receptor blockers. Preferably the compounds provided herein are allosteric NMDA inhibitors.